Evidence map›Paper›PMID 31431961›Full record

ArticleRheumatology advances in practice2018

An audit of the use of hydroxychloroquine in rheumatology clinics.

Claudia Worth, Imran H Yusuf, Bethany Turner, Hanae Gourier, Emma E Brooks, Daniel O Mort, Srilakshmi Sharma, Susan M Downes, Raashid A Luqmani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology advances in practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Claudia WorthDepartment of Rheumatology, Oxford University Hospitals, Oxford.
Imran H YusufOxford Eye Hospital, Oxford University Hospitals, Oxford.ORCID 0000-0002-0424-5852
Bethany TurnerDepartment of Rheumatology, Oxford University Hospitals, Oxford.
Hanae GourierDepartment of Emergency Medicine, Stoke Mandeville Hospital, Aylesbury.
Emma E BrooksSchool of Medicine, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, UK.
Daniel O MortSchool of Medicine, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, UK.
Srilakshmi SharmaOxford Eye Hospital, Oxford University Hospitals, Oxford.
Susan M DownesOxford Eye Hospital, Oxford University Hospitals, Oxford.
Raashid A LuqmaniNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, UK.

Funding

Medical Research Council MR/R000735/1
6 · The paper itself

Abstract

objectiveThe aim was to audit the use, indications, complications and patient information regarding HCQ treatment in rheumatology clinics in a tertiary referral centre.

methodsDuring a 9-month period, we identified all patients prescribed HCQ and attending rheumatology clinics in one hospital. We established: (i) the indication for HCQ; (ii) the prevalence of HCQ overdosing based on absolute body weight (ABW); (iii) documentation of warning of risk of retinal toxicity; (iv) systemic and ocular co-morbidities; (v) ocular symptoms during treatment; and (vi) reasons for stopping HCQ.

resultsWe identified 427 patients (104 male and 323 female). The cumulative dose of HCQ was lower in RA (median 365 g; range 6-1752 g) compared with SLE (450 g; 66-1788 g) (

conclusionHCQ therapy is being used for >5 years in 29% of patients with rheumatic diseases, with higher than recommended doses in ∼10% of patients. We recommend more rigorous scrutiny of the use of HCQ to reduce the risk of retinopathy.

Indexed as

hydroxychloroquineophthalmological screeningretinal toxicityrheumatoid arthritissystemic lupus erythematosus

Identifiers

PMID31431961
PMCPMC6649984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.